Drug Trial Radar · NCT06866405
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
550
Planned (sponsor's estimate)
Start
Apr 16, 2025
Primary completion
Feb 24, 2028
Study completion Feb 24, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the blood of nonpregnant participants who had the vaccine before.
Conditions
- RSV Infection
Interventions
RSVpreFBiological
Single Dose
PlaceboBiological
Single Dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of pregnant participants reporting local reactionsTime frame: From Day 1 Through at least Day 7 after Vaccination
- Percentage of pregnant participants reporting systemic eventsTime frame: From Day 1 Through at least Day 7 after Vaccination
- Percentage of pregnant participants reporting adverse eventsTime frame: From Day 1 through 4 weeks after vaccination
- Percentage of pregnant participants reporting serious adverse eventsTime frame: From Day 1 throughout the study
- In infant participants born to pregnant participants receiving a second dose of the study intervention, the percentage of participants reporting adverse events.Time frame: From birth through 1 month of age
- In infant participants born to pregnant participants receiving a second dose of the study intervention, the percentage of participants reporting serious adverse events and newly diagnosed medical conditions.Time frame: From birth through 6 months of age.
- Proportion of participants achieving neutralizing antibody to RSV A and RSV B at birthTime frame: At birth
Locations
99 sites in 4 countries. Site status is shown where the registry gives one.
Center for Research in Women's Health
Birmingham, Alabama · Recruiting
Children's of Alabama
Birmingham, Alabama · Recruiting
University of Alabama at Birmingham - School of Medicine
Birmingham, Alabama · Recruiting
University of Alabama at Birmingham Women & Infants Center
Birmingham, Alabama · Recruiting
USA Health Children's and Women's Hospital
Mobile, Alabama · Recruiting
USA Health Strada Patient Care Center
Mobile, Alabama · Recruiting
ClinMed, LLC
Phoenix, Arizona · Recruiting
Valleywise Comprehensive Health Center Women's Clinic
Phoenix, Arizona · Recruiting
Valleywise Health Medical Center
Phoenix, Arizona · Recruiting
Ronald Reagan UCLA Medical Center (inpatient hospital)
Los Angeles, California · Recruiting
Ronald Reagan UCLA Medical Center Drug Information Center , Dept. of Pharmaceutical Services (Drug
Los Angeles, California · Recruiting
Ronald Reagan UCLA Medical Center
Los Angeles, California · Recruiting
UCLA (outpatient clinic)
Los Angeles, California · Recruiting
UCLA Clinical and Translational Research Center (research clinic)
Los Angeles, California · Recruiting
UCLA
Los Angeles, California · Recruiting
Lucile Packard Children's Hospital-Labor and Delivery Unit
Palo Alto, California · Recruiting
Stanford Obstetrics Clinic
Palo Alto, California · Recruiting
Stanford University Medical Center
Palo Alto, California · Recruiting
Stanford University
Palo Alto, California · Recruiting
Anschutz Health Sciences Building (AHSB)
Aurora, Colorado · Recruiting
Children's Hospital Colorado
Aurora, Colorado · Recruiting
CU Research Pharmacy
Aurora, Colorado · Recruiting
University of Colorado AO1 UCH
Aurora, Colorado · Recruiting
University of Colorado Hospital Inpatient Pavilion
Aurora, Colorado · Recruiting
University of Colorado Hospital Outpatient Pavilion
Aurora, Colorado · Recruiting
University of Colorado Research II Building
Aurora, Colorado · Recruiting
Citadelle Clinical Research
North Miami Beach, Florida · Recruiting
Emerald Coast OBGYN Clinical Research
Panama City, Florida · Recruiting
Emerald Coast Pediatrics
Panama City, Florida · Recruiting
HCA Florida Gulf Coast Hospital
Panama City, Florida · Recruiting
Advanced Specialty Research
Boise, Idaho · Recruiting
Saint Alphonsus Regional Medical Center
Boise, Idaho · Recruiting
St. Luke's Boise Medical Center
Boise, Idaho · Recruiting
Clinical Research Prime
Idaho Falls, Idaho · Recruiting
Saint Alphonsus Medical Center
Nampa, Idaho · Recruiting
St. Luke's Nampa Medical Center
Nampa, Idaho · Recruiting
Accellacare - McFarland
Ames, Iowa · Recruiting
Mary Greeley Medical Center
Ames, Iowa · Recruiting
McFarland Clinic, PC
Ames, Iowa · Recruiting
The University of Kansas Hospital Investigational Drug Services
Kansas City, Kansas · Recruiting
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.